Shop by goal

Popular compounds

GHK-Cu

GLP1-RC-RT

Research resources

Certificates of Analysis

Retatrutide: Metabolic Research research guide

In short: Retatrutide (LY3437943) is an investigational triple GLP-1R / GIPR / GCGR agonist evaluated in registered clinical research. GLP1-RC-RT is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. It is studied in preclinical (cell and animal) research and is supplied strictly for laboratory use, not for human or clinical use.

Not medical advice. Retatrutide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.

Retatrutide at a glance

Compound type

Research peptide

Research category

Metabolic Research

Also known as

GGG Triple Agonist, GLP-1/GIP/Glucagon Receptor Triple Agonist, Tri-Agonist

Molecular weight

4,894.6 Da

Research-grade purity

>99% HPLC

Evidence context

Preclinical / research use only

Regulatory status

Not an approved medicine. Supplied as a research compound

Last reviewed

14 August 2026

What to know first

Receptor pharmacology: agonist activity characterised at GLP-1R, GIPR and GCGR in published in-vitro studies

GIPR potency reported as 8.9-fold that of native GIP in receptor-pharmacology studies

Albumin-binding C20 fatty-diacid modification investigated as a contributor to prolonged systemic exposure

Phase 2 obesity RCT (NEJM 2023, PMID 37385275): investigators reported −24.2% mean change from baseline in body weight at week 48 (12 mg arm)

Details and limits sit in the sections below. Research use only.

What Retatrutide is

GLP1-RC-RT is a triple GLP-1R / GIPR / GCGR agonist research compound, commonly referred to as “Reta” in research communities.

One-paragraph overview from our research datasheet. Still scientific, but faster to read than the full mechanism list below.

Retatrutide (LY3437943) is an investigational triple GLP-1R / GIPR / GCGR agonist evaluated in registered clinical research. GLP1-RC-RT is the New-U catalogue identifier for the analytically verified laboratory research material supplied here.

Research contexts

Peer-reviewed papers discuss Retatrutide in specific lab settings. The points below reflect research questions, not health claims.

Research vs. personal use: Literature describes experiments in cells and animals. That is distinct from real-world use. Our products are for laboratory research only.

Typical study contexts

Incretin pathways, food intake and glucose handling in rodent models.

Some drug-class molecules have clinical trials. Those are distinct from catalogue research use.

Receptor pharmacology: agonist activity characterised at GLP-1R, GIPR and GCGR in published in-vitro studies.

GIPR potency reported as 8.9-fold that of native GIP in receptor-pharmacology studies.

Albumin-binding C20 fatty-diacid modification investigated as a contributor to prolonged systemic exposure.

Phase 2 obesity RCT (NEJM 2023, PMID 37385275): investigators reported −24.2% mean change from baseline in body weight at week 48 (12 mg arm).

Why Metabolic Research research matters

Metabolic-research peptides are studied for incretin-receptor pharmacology and energy-balance endpoints. The literature reports mechanisms and study endpoints, not guidance for any use.

Mechanisms (technical review)

Our datasheet lists mechanistic themes from preclinical work. These are research endpoints, not health claims.

Receptor pharmacology: agonist activity characterised at GLP-1R, GIPR and GCGR in published in-vitro studies

GIPR potency reported as 8.9-fold that of native GIP in receptor-pharmacology studies

Albumin-binding C20 fatty-diacid modification investigated as a contributor to prolonged systemic exposure

Phase 2 obesity RCT (NEJM 2023, PMID 37385275): investigators reported −24.2% mean change from baseline in body weight at week 48 (12 mg arm)

Phase 3 TRIUMPH-1 (NCT05929066; sponsor-reported topline, ADA 2026; not yet peer-reviewed): investigators reported −28.3% mean change from baseline in body weight at week 80 (12 mg arm)

Phase 2a MASLD trial (Nat Med 2024): investigators reported up to 82.4% relative reduction in hepatic fat fraction

Lab handling & preparation

Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation.. See the storage guide.

Published pharmacokinetic context: Published pharmacokinetic research reports dose-proportional exposure, an apparent elimination half-life of approximately 6 days and Tmax of 12–72 h under the investigated protocols, with hepatic metabolism and no CYP-mediated interaction reported. Phase 3 TRIUMPH-1 (obesity) topline was reported by the sponsor in 2026 and is not yet peer-reviewed; further TRIUMPH readouts (type 2 diabetes, cardiovascular/kidney outcomes) remain registered.

Purity check: Use the COA reading guide and the published Retatrutide Certificate of Analysis.

Common Questions People Are Asking

What is GLP1-RC-RT?

GLP1-RC-RT is New-U's catalogue designation for this analytically verified research compound, commonly referred to as “Reta” within research communities. It is supplied as laboratory research material: not a medicine, a treatment, a generic pharmaceutical or a therapeutic product, not equivalent to any clinical or commercial product, and not offered for human or veterinary use.

Which receptor systems have been investigated?

Published in-vitro pharmacology characterises agonist activity at three receptors: GLP-1R (reported EC50 0.775 nM), GIPR (reported EC50 0.0643 nM, with potency reported as 8.9-fold that of native GIP) and GCGR (reported EC50 5.79 nM). Structural work additionally investigates the C20 fatty-diacid albumin-binding modification as a contributor to prolonged systemic exposure, and Aib/α-methylleucine substitutions for altered proteolytic stability.

What analytical testing accompanies GLP1-RC-RT?

Each released GLP1-RC-RT batch is tested by an independent analytical laboratory (Janoshik Analytical or Freedom Diagnostics) for purity by RP-HPLC area normalisation and for identity by mass spectrometry, and the result is published as a batch-linked Certificate of Analysis recording the laboratory, report number, measured purity and test date. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Where can I view the current batch COA for GLP1-RC-RT?

The current batch certificate — laboratory, report number, measured purity and test date — is published at /coa/retatrutide, together with the testing history for the compound. It is readable before ordering rather than on request afterwards.

What does >99% HPLC purity mean?

It is a purity figure obtained by reversed-phase high-performance liquid chromatography using area normalisation: the target peak accounts for more than 99% of the total integrated peak area in the chromatogram for the tested sample. It is a statement about chemical purity of that sample only. It does not describe sterility, endotoxin content, heavy-metal content, pharmaceutical equivalence or any clinical property.

What clinical trials are referenced on this page?

Three external studies of the investigational compound: the randomised Phase 2 obesity trial (Jastreboff et al., N Engl J Med 2023; PMID 37385275, DOI 10.1056/NEJMoa2301972), the Phase 2a MASLD trial (Sanyal et al., Nat Med 2024; DOI 10.1038/s41591-024-03018-2) and the Phase 3 TRIUMPH-1 trial (ClinicalTrials.gov NCT05929066). Each reported result on this page is attributed to its study, arm and timepoint. TRIUMPH-1 figures are sponsor-reported topline presented at ADA 2026 and have not yet been peer-reviewed; the Phase 2 and Phase 2a figures come from peer-reviewed journal publications.

How is published clinical research distinguished from New-U batch testing?

They are separate bodies of evidence and this page keeps them apart. Published clinical research is external work on Retatrutide as an investigational compound, using those studies' own materials and protocols; it establishes nothing about the material supplied here. New-U batch testing is analytical work on the GLP1-RC-RT lot itself — RP-HPLC purity and mass-spectrometry identity — and it establishes nothing clinical. A certificate of analysis combined with an external clinical paper does not amount to clinical validation of GLP1-RC-RT.

What form is GLP1-RC-RT supplied in?

GLP1-RC-RT is supplied as a lyophilised powder in sealed vials, in single-vial laboratory samples and sealed 10-vial research packs across the listed strengths, with a batch-linked Certificate of Analysis.

How should laboratory research material be stored?

Store the lyophilised powder in a freezer at −20 °C. If a laboratory protocol requires the material in solution, hold the resulting solution refrigerated at 1–6 °C, protected from light, and avoid repeated freeze–thaw cycles, which can degrade the fatty-acid modification. Storage conditions are laboratory handling information only.

How does this receptor profile differ from the dual and single agonists?

The three classes are distinguished by receptor coverage: the semaglutide literature describes GLP-1R agonism, the tirzepatide literature describes GIPR/GLP-1R agonism, and this compound is investigated for GLP-1R/GIPR/GCGR agonism. Their clinical programmes were conducted separately, so published results from one programme are not head-to-head comparisons with another.

Is GLP1-RC-RT an approved medicine?

No. The associated compound is investigational and is being evaluated in registered clinical studies; it is not approved in any jurisdiction. The material supplied here is laboratory research material and is not offered as a medicine, therapeutic product, or material for human or veterinary use.

Is this page medical advice? Can I use Retatrutide for my health?

No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.

Where do I find Retatrutide specs, purity certificates and pricing?

Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.

Related peptide guides

Other compounds researchers often read about alongside Retatrutide.

Semaglutide - companion guide

Tirzepatide - companion guide

Cagrilintide - companion guide

Eloralintide - companion guide

Scientific sources & further reading

Primary literature and registries for Retatrutide, plus mainstream coverage of the peptide category. Research use only - not medical advice.

Databases & literature:

PubMed: peer-reviewed literature on Retatrutide

ClinicalTrials.gov: registered studies on Retatrutide

Retatrutide: Wikipedia (search)

Peptides in the news:

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Ready to order? View full product specs

Access concentration, batch info, variants, and current pricing on our shop.

Also known as: GGG Triple Agonist, GLP-1/GIP/Glucagon Receptor Triple Agonist, Tri-Agonist

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research